Group 4 Created with Sketch.
Your changes have been saved

Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Chan

Share
station description Thought leader perspectives on current clinical advances in medicine
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Duration: 01:00:04
Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon complet
Snippets are a new way to share audio!
You can clip a small part of any file to share, add to playlist, and transcribe automatically. Just click the to create your snippet!
Snippets: Clips of Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Chan that people like
There are currently no snippets from Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Chan.
Snippets are an easy way to highlight your favorite soundbite from any piece of audio and share with friends, or make a trailer for PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Playlists that Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Chan appears on.
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Add to Playlist
Up Next
Full Description
Back to Top
Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.
Up Next
Add to playlist
New playlist

Embed

COPY
Embed Options
Create Playlist
Select the Station you want to upload this audio to
Station
0 / 140
0 / 2000
Playlist Icon Image:
(.jpg, .png, min size 500x500px)
Privacy
Subscribers
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Password reset

Enter your email address that you used to register. We'll send you an email with your username and a link to reset your password.



If you still need help, contact Vurbl Support
Password reset sent

You have been sent instructions on resetting you password to the email associated with your account. Please check your email and signing in again.


Back to Sign In
If you still need help, contact Vurbl Support
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Reset password

Please enter your new password below.



If you still need help, contact Vurbl Support
Your voice matters.
Discover & Listen to the world’s largest free collection of audio
Verify Email

Enter your email address that you used to register. We'll send you an email with a link to verify your email.



Cancel
Delete Profile
Are you sure? We will miss you :'(
Delete
Delete Audio
Are you sure?
Delete
Delete Playlist
Are you sure you want to delete this playlist?
Delete
Notifications
You must be signed in to view
your notifications. Please sign in
Edit Snippet
0 / 140
0 / 140